PMID- 27358859
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160630
LR  - 20200930
IS  - 2306-9759 (Print)
IS  - 2313-0792 (Electronic)
IS  - 2306-9759 (Linking)
VI  - 1
DP  - 2014
TI  - Reactive oxygen species in eradicating acute myeloid leukemic stem cells.
PG  - 13
LID - 10.3978/j.issn.2306-9759.2014.04.03 [doi]
LID - 13
AB  - Leukemic stem cells (LSCs) have been proven to drive leukemia initiation, 
      progression and relapse, and are increasingly being used as a critical target for 
      therapeutic intervention. As an essential feature in LSCs, reactive oxygen 
      species (ROS) homeostasis has been extensively exploited in the past decade for 
      targeting LSCs in acute myeloid leukemia (AML). Most, if not all, agents that 
      show therapeutic benefits are able to alter redox status by inducing ROS, which 
      confers selectivity in eradicating AML stem cells but sparing normal 
      counterparts. In this review, we provide the comprehensive update of 
      ROS-generating agents in the context of their impacts on our understanding of the 
      pathogenesis of AML and its therapy. We anticipate that further characterizing 
      these ROS agents will help us combat against AML in the coming era of 
      LSC-targeting strategy.
FAU - Zhang, Hui
AU  - Zhang H
AD  - 1 State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, 
      Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 
      200025, China ; 2 Pediatric department, The First Affiliated Hospital of 
      Guangzhou Medical University, Guangzhou 510120, China.
FAU - Fang, Hai
AU  - Fang H
AD  - 1 State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, 
      Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 
      200025, China ; 2 Pediatric department, The First Affiliated Hospital of 
      Guangzhou Medical University, Guangzhou 510120, China.
FAU - Wang, Kankan
AU  - Wang K
AD  - 1 State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, 
      Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 
      200025, China ; 2 Pediatric department, The First Affiliated Hospital of 
      Guangzhou Medical University, Guangzhou 510120, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140607
PL  - China
TA  - Stem Cell Investig
JT  - Stem cell investigation
JID - 101672113
PMC - PMC4923509
OTO - NOTNLM
OT  - Acute myeloid leukemia (AML)
OT  - leukemic stem cells (LSCs)
OT  - reactive oxygen species (ROS)
OT  - targeting therapy
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2014/01/01 00:00
MHDA- 2014/01/01 00:01
PMCR- 2014/06/07
CRDT- 2016/07/01 06:00
PHST- 2014/02/07 00:00 [received]
PHST- 2014/04/20 00:00 [accepted]
PHST- 2016/07/01 06:00 [entrez]
PHST- 2014/01/01 00:00 [pubmed]
PHST- 2014/01/01 00:01 [medline]
PHST- 2014/06/07 00:00 [pmc-release]
AID - sci-01-2014.04.03 [pii]
AID - 10.3978/j.issn.2306-9759.2014.04.03 [doi]
PST - epublish
SO  - Stem Cell Investig. 2014 Jun 7;1:13. doi: 10.3978/j.issn.2306-9759.2014.04.03. 
      eCollection 2014.